Lead optimisation support from Scilife DDD

Inicure's founders and researchers Professor Johan Bylund at the University of Gothenburg, together with Dr Peter Olofsson-Sahl at University West, have received support from the national drug discovery platform at SciLifeLab. The lead candidates have shown strong potential, particularly for severe infections like chronic urinary tract and lung infections.

With the help of DDD, they will focus on optimising these compounds to meet industry standards, bringing them closer to clinical use as a much-needed alternative for life-threatening infections. The current project is going very well and we have already reached some very promising improved pre-CD molecules, and hope to be able to nominate our CD in mid 2026.